Clinical Efficacy of Conservative Treatment with Micronized Purified Flavonoid Fraction in Female Patients with Pelvic Congestion Syndrome.
Rustem V Akhmetzianov, Roman A Bredikhin
https://pubmed.ncbi.nlm.nih.gov/34537951/Actively Recruiting
Led by Pirogov Russian National Research Medical University · Updated on 2024-12-27
150
Participants Needed
1
Research Sites
4 weeks
Total Duration
Researchers are evaluating the effectiveness and safety of different venoactive drugs VADs in treating female patients with pelvic venous disorders PeVD, which include conditions like varicose veins in the pelvis and vulva and compression of certain veins. PeVD causes chronic pelvic pain CPP, which greatly affects quality of life, daily activities, and emotional well-being in women. This study aims to compare three diosmin-containing VADs in their ability to relieve CPP and assess patient adherence and side effects. The trial involves 150 women aged 18 to 45 with symptomatic PeVD. Participants are randomly assigned into three groups of 50 each to receive one of the following treatments micronized purified flavonoid fraction MPFF 1000 mg once daily, diosmin 600 mg once daily, or a combination of hesperidin and diosmin 1000 mg once daily. Each treatment lasts for two months, with patients taking their medication every morning during breakfast. Diagnosis and disease characteristics are confirmed using transabdominal and transvaginal duplex ultrasound scans. During the study, participants will record their pelvic pain weekly using a 10-point visual analogue scale VAS. Researchers will monitor pain levels, side effects, and adherence throughout the 8-week treatment. Clinical exams and data collection will occur before and after treatment. Patients are instructed to report any side effects immediately. The main outcome measure is the severity of chronic pelvic pain, assessed weekly. Secondary outcomes include monitoring side effects and adverse events. The study duration for each participant is approximately two months of treatment.
CONDITIONS
Venoactive Drug Treatment of Pelvic Venous Disorders
S
Sergey G Gavrilov, MD, PhD
A
Alexander V Alenichev
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Pirogov Russian National Research Medical University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 2 months
Participants take one of three venoactive drugs once daily for 2 months to treat pelvic venous disorders and relieve chronic pelvic pain. They self-rate their pain intensity weekly using a visual analogue scale and report any side effects or adverse events to the study doctor immediately.
Weekly visits or contacts for pain assessment and safety monitoring
Duration - 1 day
At the end of treatment, participants undergo a repeated clinical examination and provide completed pain assessment forms to evaluate treatment efficacy and safety.
1 visit (in-person) after treatment completion
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Rustem V Akhmetzianov, Roman A Bredikhin
https://pubmed.ncbi.nlm.nih.gov/34537951/Andrew Nicolaides, Stavros Kakkos, Niels Baekgaard...
https://pubmed.ncbi.nlm.nih.gov/29871479/Sergey G Gavrilov, Yekaterina P Moskalenko, Anatoly V Karalkin
https://pubmed.ncbi.nlm.nih.gov/30468077/Marianne G De Maeseneer, Stavros K Kakkos, Thomas Aherne...
https://pubmed.ncbi.nlm.nih.gov/35027279/M Simsek, F Burak, O Taskin
https://pubmed.ncbi.nlm.nih.gov/17629162/Maria José Martinez-Zapata, Robin Wm Vernooij, Daniel Simancas-Racines...
https://pubmed.ncbi.nlm.nih.gov/33141449/Pier-Luigi Antignani, Zaza Lazarashvili, Javier L Monedero...
https://pubmed.ncbi.nlm.nih.gov/31345010/Sergey G Gavrilov, Yekaterina P Moskalenko, Anastasiya S Grishenkova...
https://pubmed.ncbi.nlm.nih.gov/40855727/Pirogov Russian National Research Medical University
Lead Sponsor